AHUS‐related mutations in Factor H are associated with increased platelet activation due to dysregulated alternative pathway activity,33, 147 and thus the study by Saggu et al.31 gives rise to the possibility that inhibition of properdin could have beneficial effects on platelet activation in patients suffering from aHUS. Here, CFP is linked to atypical hemolytic-uremic syndrome.